ORIC
ORIC Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.86
+0.95%Aug 7, 2026, 20:30 UTC
ORIC Pharmaceuticals granted 125,400 non-qualified stock options and 20,550 restricted stock units to five new non-executive employees on August 3, 2026, as inducement grants under Nasdaq Listing Rule 5635(c)(4).
Source:Jul 14, 2026, 20:05 UTC
ORIC Pharmaceuticals initiated the Himalayas-1 global Phase 3 trial of rinzimetostat in combination with darolutamide for mCRPC patients previously treated with abiraterone.